Lisa M. Sullivan
Boston University
310 Papers
2.7K Citations
Lisa M. Sullivan is an academic researcher from Boston University. The author has contributed to research in topics: Medicine & Framingham Heart Study. The author has an hindex of 94, co-authored 308 publications. Previous affiliations of Lisa M. Sullivan include Columbia University & Children's Hospital of Philadelphia.
Chat about Author
Papers
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.
Ralph B. D'Agostino,Ralph B. D'Agostino,Scott M. Grundy,Lisa M. Sullivan,Lisa M. Sullivan,Peter W.F. Wilson,Peter W.F. Wilson +6 more
TL;DR: The sex-specific Framingham CHD prediction functions perform well among whites and blacks in different settings and can be applied to other ethnic groups after recalibration for differing prevalences of risk factors and underlying rates of CHD events.
2.3K
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
TL;DR: The metabolic syndrome accounts for up to one third of CVD in men and approximately half of new T2DM over 8 years of follow-up, and is associated with an increased risk for CVD and T2 DM in both sexes.
2.1K
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.
TL;DR: The overweight category is associated with increased relative and population attributable risk for hypertension and cardiovascular sequelae and interventions to reduce adiposity and avoid excess weight may have large effects on the development of risk factors and cardiovascular disease at an individual and population level.
2K
Presentation of multivariate data for clinical use: The Framingham Study risk score functions.
TL;DR: An effort to make available a tool for clinicians to aid in their decision‐making process regarding treatment and to assist them in motivating patients toward healthy behaviours is made available.
1.5K
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Joseph P. McEvoy,Jonathan M. Meyer,Donald C. Goff,Henry A. Nasrallah,Sonia M. Davis,Lisa M. Sullivan,Herbert Y. Meltzer,John K. Hsiao,T. Scott Stroup,Jeffrey A. Lieberman +9 more
TL;DR: The metabolic syndrome is highly prevalent in US schizophrenia patients and represents an enormous source of cardiovascular risk, especially for women, so clinical attention must be given to monitoring for this syndrome, and minimizing metabolic risks associated with antipsychotic treatment.
1.2K